journal article·2021-12-15

Self-Assembled Oligo-Urethane Nanoparticles: Their Characterization and Use for the Delivery of Active Biomolecules into Mammalian Cells

Suja Shrestha, Meghan J. McFadden, Allen C. T. Teng, Patrick Dong Min Chang, Joyce Deng, Tatianna W. Y. Wong, Ronald D. Cohn, Evgueni A. Ivakine, Anthony O. Gramolini, J. Paul Santerre

ACS Applied Materials & Interfaces· Volume 13· Issue 49
Publisher page

Abstract

Developing safe and effective strategies to deliver biomolecules such as oligonucleotides and proteins into cells has grown in importance over recent years, with an increasing demand for non-viral methods that enable clinical translation. Here, we investigate uniquely configured oligo-urethane nanoparticles based on synthetic chemistries that minimize the release of pro-inflammatory biomarkers from immune cells, show low cytotoxicity in a broad range of cells, and efficiently deliver oligonucleotides and proteins into mammalian cells. The mechanism of cell uptake for the self-assembled oligo-urethane nanoparticles was shown to be directed by caveolae-dependent endocytosis in murine myoblasts (C2C12) cells. Inhibiting caveolae functions with genistein and methyl-β-cyclodextrin limited nanoparticle internalization. The nanoparticles showed a very high delivery efficiency for the genetic material (a 47-base oligonucleotide) (∼80% incorporation into cells) as well as the purified protein (full length firefly luciferase, 67 kDa) into human embryonic kidney (HEK293T) cells. Luciferase enzyme activity in HEK293T cells demonstrated that intact and functional proteins could be delivered and showed a significant extension of activity retention up to 24 h, well beyond the 2 h half-life of the free enzyme. This study introduces a novel self-assembled oligo-urethane nanoparticle delivery platform with very low associated production costs, enabled by their scalable chemistry (the benchwork cost is $ 0.152/mg vs $ 974.6/mg for typical lipid carriers) that has potential to deliver both oligonucleotides and proteins for biomedical purposes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Dentistry, University of Toronto, Toronto M5G 1G6, Ontario, Canada

Translational Biology and Engineering Program and Ted Rogers Centre for Heart Research, Toronto M5G 1M1, Ontario, Canada

Institute of Biomedical Engineering, University of Toronto, Toronto M5S 3G9, Ontario, Canada

Department of Physiology, University of Toronto, Toronto M5S 1A8, Ontario, Canada

Department of Chemical Engineering & Applied Chemistry, Faculty of Engineering, University of Toronto, Toronto M5S 3E5, Canada

Genetics & Genome Biology Program, The Hospital for Sick Children, Toronto M5G 0A4, Ontario, Canada

Department of Molecular & Medical Genetics and Paediatrics, Faculty of Medicine, University of Toronto, Toronto M5S 1A8, Ontario, Canada

Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto M5G 0A4, Ontario, Canada

Funding

Medicine by Design New Ideas Fund · Jesse's Journey-The Foundation for Gene and Cell Therapy

References (69)

Show source-provided references
1. 10.1038/nchem.262910.1038/nchem.2629 ↗
2. 10.1038/ncomms1227710.1038/ncomms12277 ↗
3. 10.1038/natrevmats.2017.5610.1038/natrevmats.2017.56 ↗
4. 10.1038/s41573-020-0075-710.1038/s41573-020-0075-7 ↗
5. 10.1038/s41565-019-0539-210.1038/s41565-019-0539-2 ↗
6. 10.1038/s41551-017-0137-210.1038/s41551-017-0137-2 ↗
7. 10.1016/j.smim.2017.08.01510.1016/j.smim.2017.08.015 ↗
8. 10.1002/anie.20150591310.1002/anie.201505913 ↗
9. 10.1073/pnas.121870511010.1073/pnas.1218705110 ↗
10. 10.1038/nchem.277910.1038/nchem.2779 ↗
11. 10.1021/acsnano.8b0105910.1021/acsnano.8b01059 ↗
12. 10.1073/pnas.152024411310.1073/pnas.1520244113 ↗
13. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
14. 10.1021/acsnano.6b0760010.1021/acsnano.6b07600 ↗
15. 10.1016/j.jconrel.2008.02.00710.1016/j.jconrel.2008.02.007 ↗
16. 10.1016/j.biomaterials.2010.06.03810.1016/j.biomaterials.2010.06.038 ↗
17. 10.1038/nbt.333010.1038/nbt.3330 ↗
18. 10.1039/c0cs00003e10.1039/c0cs00003e ↗
19. 10.1016/j.biomaterials.2005.05.07910.1016/j.biomaterials.2005.05.079 ↗
20. 10.1016/j.biomaterials.2004.11.03510.1016/j.biomaterials.2004.11.035 ↗
21. 10.1016/j.biomaterials.2005.06.02010.1016/j.biomaterials.2005.06.020 ↗
22. 10.1002/jbm.a.3119410.1002/jbm.a.31194 ↗
23. 10.1021/bm900419410.1021/bm9004194 ↗
24. 10.1016/j.biomaterials.2011.03.03410.1016/j.biomaterials.2011.03.034 ↗
25. 10.1002/jcb.2330710.1002/jcb.23307 ↗
26. 10.1016/j.biomaterials.2011.04.04810.1016/j.biomaterials.2011.04.048 ↗
27. 10.1016/j.actbio.2015.05.03810.1016/j.actbio.2015.05.038 ↗
28. 10.1016/j.biomaterials.2011.01.06910.1016/j.biomaterials.2011.01.069 ↗
29. 10.1016/j.biomaterials.2012.08.01410.1016/j.biomaterials.2012.08.014 ↗
30. 10.1016/j.actbio.2013.12.02210.1016/j.actbio.2013.12.022 ↗
31. 10.1016/j.actbio.2020.04.04210.1016/j.actbio.2020.04.042 ↗
32. 10.1089/ten.tea.2014.054810.1089/ten.tea.2014.0548 ↗
33. 10.1016/j.actbio.2019.06.04610.1016/j.actbio.2019.06.046 ↗
34. 10.1016/j.jconrel.2017.02.00810.1016/j.jconrel.2017.02.008 ↗
35. 10.1016/j.actbio.2019.03.01410.1016/j.actbio.2019.03.014 ↗
36. 10.1016/j.addr.2013.12.00910.1016/j.addr.2013.12.009 ↗
37. 10.1016/j.ejps.2010.06.00710.1016/j.ejps.2010.06.007 ↗
38. 10.1039/c5nr01695a10.1039/c5nr01695a ↗
39. 10.1021/acsami.8b0752910.1021/acsami.8b07529 ↗
40. Stability Testing of New Drug Substances and Products Q1A(R2); ICH Harmonized Tripartite Guideline, 2003; pp 1–18.
41. 10.1039/c8bm00637g10.1039/c8bm00637g ↗
42. 10.1016/j.foodchem.2016.03.00810.1016/j.foodchem.2016.03.008 ↗
43. 10.1039/c4cs00487f10.1039/c4cs00487f ↗
44. 10.1021/la026842o10.1021/la026842o ↗
45. 10.1002/cphc.20040052710.1002/cphc.200400527 ↗
46. 10.1016/s0378-5173(98)00092-110.1016/s0378-5173(98)00092-1 ↗
47. Riddick T. M. · 1968
48. 10.1016/j.ijpharm.2009.10.01810.1016/j.ijpharm.2009.10.018 ↗
49. 10.1021/nn700256c10.1021/nn700256c ↗
50. 10.1186/1743-8977-7-2210.1186/1743-8977-7-22 ↗
51. 10.1016/j.toxlet.2012.12.01910.1016/j.toxlet.2012.12.019 ↗
52. 10.1161/circresaha.116.30994710.1161/circresaha.116.309947 ↗
53. 10.1159/00050509910.1159/000505099 ↗
54. 10.1007/s10439-016-1580-z10.1007/s10439-016-1580-z ↗
55. FDA. Pyrogen and Endotoxins Testing: Questions and Answers. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-pyrogen-and-endotoxins-testing-questions-and-answers#_Toc315937935 (accessed March 25, 2019).
56. 10.1242/dmm.04536910.1242/dmm.045369 ↗
57. 10.1002/anie.20180694110.1002/anie.201806941 ↗
58. 10.2147/IJN.S7415810.2147/IJN.S74158 ↗
59. 10.1016/j.actbio.2013.02.03410.1016/j.actbio.2013.02.034 ↗
60. 10.1007/s00018-009-0053-z10.1007/s00018-009-0053-z ↗
61. 10.1186/1477-3155-12-510.1186/1477-3155-12-5 ↗
62. 10.1042/bj2003125310.1042/bj20031253 ↗
63. 10.1016/j.addr.2007.06.00810.1016/j.addr.2007.06.008 ↗
64. 10.2147/ijn.s19910410.2147/ijn.s199104 ↗
65. 10.1002/bit.2005910.1002/bit.20059 ↗
66. 10.1016/0378-1119(91)90270-l10.1016/0378-1119(91)90270-l ↗
67. 10.1007/s11095-008-9800-310.1007/s11095-008-9800-3 ↗
68. 10.1016/j.jconrel.2003.08.00510.1016/j.jconrel.2003.08.005 ↗
69. 10.1074/mcp.m113.03159110.1074/mcp.m113.031591 ↗